conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 17, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Kristina
Toliver at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
http://www.fda.gov/
AdvisoryCommittees/
ucm11462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 30, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–16862 Filed 7–5–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0002]

Blood Products Advisory Committee;
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
general public.

Name of Committee: Blood Products
Advisory Committee.

General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.

Date and Time: The meeting will be
held on August 2, 2011, from 1:30 p.m.
to 5 p.m. and on August 3, 2011, from
8 a.m. to 2:30 p.m.

Location: Hilton Hotel, Washington,
DC North Gaithersburg, 620 Perry
Pkwy., Gaithersburg, MD 20877, 301–
977–8900. For those unable to attend in
person, the meeting will also be Web
cast. The Web cast will be available at
the following links.

Blood Products Advisory Committee
Day 1: http://fda.yorkcast.com/webcast/
Viewer/?peid=6bc0d0d80a
594dd9d362ad6b1815b4491d.

Blood Products Advisory Committee
Day 2: http://fda.yorkcast.com/webcast/
Viewer/?peid=6844630c50847c5aacb
06b1729f203f1d.

Contact Person: Bryan Emery or
Rosanna Harvey, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.

Agenda: On August 2, 2011, the
committee will discuss a study on the
incidence of Trypanosoma cruzi
infection in blood donors and its
implications for selective testing of
blood donors. On August 3, 2011, the
committee will discuss measures to
preserve the blood supply during a
severe emergency. In the afternoon, the
committee will hear the following updates: Summary of the June 7–8,
2011, Health and Human Services
Advisory Committee on Blood Safety
and Availability meeting; summary of
the May 17–18, 2011, public workshop
on risk mitigation strategies to address
procoagulant activity in immune
globulin products; and summary of the
August 1–2, 2011, Transmissible
Spongiform Encephalopathies Advisory
Committee meeting.

FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at http://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.

Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 26, 2011. Oral
presentations from the public will be
scheduled on August 2, 2011, between
approximately 3:30 and 4 p.m. and on
August 3, 2011, between approximately
11 and 11:30 a.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before July 18,
2011. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
close a lottery to determine the
speakers if the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 19, 2011.

Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.

FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Bryan Emery
or Rosanna Harvey at least 7 days in
advance of the meeting.

FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
http://www.fda.gov/Advisory
Committees/Calendar/default.htm. Scroll down to the
appropriate advisory committee link.